Department of Therapeutic Chemistry, National Research Centre, Dokki, Giza 12622, Egypt.
Department of Chemistry & Physics, Augusta University, Augusta, GA 30912, US.
Bioorg Chem. 2021 Dec;117:105466. doi: 10.1016/j.bioorg.2021.105466. Epub 2021 Nov 4.
Series of piperidone-salicylate conjugates were synthesized through the reaction of 3E,5E-bis(arylidene)-4-piperidones with the appropriate acid chloride of acetylsalicylate in the presence of triethylamine. All the synthesized conjugates reveal antiproliferative properties against A431 (squamous skin) cancer cell line with potency higher than that of 5-fluorouracil. Many of the synthesized agents also exhibit promising antiproliferative properties against HCT116 (colon) cancer cell line, of which 5o and 5c are the most effective with 12.9, 9.8 folds potency compared with Sunitinib. Promising activity is also shown against MCF7 (breast) cancer cell line with 1.19, 1.12 folds relative to 5-fluorouracil. PI-flow cytometry of compound 5c supports the arrest of cell cycle at G1-phase. However, compound 5o and Sunitinib arrest the cell cycle at S-phase. The synthesized conjugates can be considered as multi-targeted tyrosine kinase inhibitors due to the promising properties against VEGFR-2 and EGFR in MCF7 and HCT116. CDOCKER studies support the EGFR inhibitory properties. Compounds 5p and 5i possessing thienylidene heterocycle are anti-SARS-CoV-2 with high therapeutic indices. Many of the synthesized agents show enhanced COX-1/2 properties than aspirin with better selectivity index towards COX-2 relative to COX-1. The possible applicability of the potent candidates discovered as antitumor and anti-SARS-CoV-2 is supported by the safe profile against normal (non-cancer, RPE1 and VERO-E6) cells.
一系列的哌啶酮-柳酸盐缀合物是通过 3E,5E-双(亚苄基)-4-哌啶酮与适当的乙酰柳酸盐的酰氯在三乙胺存在下反应合成的。所有合成的缀合物都显示出对 A431(鳞状皮肤)癌细胞系的抗增殖活性,其活性高于 5-氟尿嘧啶。许多合成的试剂对 HCT116(结肠)癌细胞系也表现出有希望的抗增殖活性,其中 5o 和 5c 的活性最高,与舒尼替尼相比,其活性分别提高了 12.9 倍和 9.8 倍。对 MCF7(乳腺)癌细胞系也表现出有希望的活性,与 5-氟尿嘧啶相比,其活性分别提高了 1.19 倍和 1.12 倍。化合物 5c 的 PI-流式细胞术支持细胞周期在 G1 期的停滞。然而,化合物 5o 和舒尼替尼使细胞周期在 S 期停滞。由于对 MCF7 和 HCT116 中的 VEGFR-2 和 EGFR 具有有希望的性质,这些合成的缀合物可以被认为是多靶点酪氨酸激酶抑制剂。CDOCKER 研究支持 EGFR 抑制性质。具有噻吩亚甲基杂环的化合物 5p 和 5i 具有抗 SARS-CoV-2 的高治疗指数。许多合成的试剂显示出比阿司匹林更强的 COX-1/2 性质,并且相对于 COX-1,对 COX-2 的选择性指数更好。发现的有效候选物作为抗肿瘤和抗 SARS-CoV-2 的潜在应用,得到了对正常(非癌症、RPE1 和 VERO-E6)细胞的安全特性的支持。